Overview

* Omeros ( OMER ) Q3 net loss narrows to $30.9 mln from $32.2 mln in prior year

* Company entered into a $2.1 bln asset purchase agreement with Novo Nordisk

* Omeros ( OMER ) prepares for potential FDA approval of narsoplimab in TA-TMA

Outlook

* Omeros expects to receive $240 mln upfront from Novo Nordisk deal in Q4 2025

* Company anticipates FDA decision on narsoplimab by December 26, 2025

Result Drivers

* EXPENSE REDUCTION - Omeros ( OMER ) reduced expenditures on various programs to conserve capital for the expected commercial launch of narsoplimab in TA-TMA

* NOVO NORDISK AGREEMENT - Omeros ( OMER ) entered an agreement with Novo Nordisk for up to $2.1 bln in payments, including $240 mln upfront, for rights to zaltenibart

* NARSOPLIMAB PREPARATIONS - Omeros ( OMER ) is preparing for the potential FDA approval of narsoplimab, including assembling a commercial team and engaging with stakeholders

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.47

Q3 Net -$30.90

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Omeros Corp ( OMER ) is $36.00, about 80.9% above its November 12 closing price of $6.89

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)